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Abstract 38 
Ever since the first case was reported at the end of 2019, the SARS-COV-2 virus and associated 39 
lung disease COVID-19 has spread throughout the world and has become a pandemic. In 40 
particular, the high transmission rate of the virus has made it a threat to public health globally. 41 
Currently, there is no proven effective therapy against the virus, and the impact on other 42 
diseases is also uncertain, especially inherited arrhythmia syndrome. 43 
Arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease 44 
outcome. This may be of importance for patients with an increased risk for cardiac arrhythmias, 45 
either secondary to acquired conditions or co-morbidities or consequent to inherited syndromes. 46 
Management of patients with inherited arrhythmia syndromes such as Long QT syndrome, 47 
Brugada syndrome, Short QT syndrome and Catecholaminergic Polymorphic Ventricular 48 
Tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. 49 
Depending on the inherited defect involved, these patients may be susceptible to pro-50 
arrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances 51 
and use of antiviral drugs. We here describe the potential COVID-19 associated risks and 52 
therapeutic considerations for patients with distinct inherited arrhythmia syndromes and 53 
provide recommendations, pending local possibilities, for their monitoring and management 54 
during this pandemic. 55 
  56 
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Introduction 57 
Ever since the first case was reported at the end of 2019, the SARS-COV-2 virus and 58 
associated lung disease COVID-19 has spread throughout the world and has become a 59 
pandemic. In particular, the high transmission rate of the virus has made it a threat to public 60 
health globally.1,2 Currently, there is no proven effective therapy against the virus, and the 61 
impact on other diseases is also uncertain. 62 
 SARS-CoV-2 is an RNA virus, a member of coronavirus family of viruses, similar to 63 
SARS-CoV.3 Like SARS-CoV, SARS-CoV-2 infects humans by binding to the angiotensin-64 
converting enzyme 2 (ACE2) receptor on the surface of the cell through its spike domain.3 65 
Infected patients present with a variety of manifestations. The most common clinical symptom 66 
is fever (88.7%). Other symptoms include cough (67.8%), shortness of breath (18.7%), myalgia 67 
or arthralgia (14.9%), headache (13.6%), diarrhea (3.8%), sore throat (13.9%), and sputum 68 
production (33.7%) and fatigue (38.1%).4 Studies have shown that while the vast majority of 69 
patients have minor symptoms, it is also possible for infected cases to become critically ill, 70 
especially older individuals (above 60 years old) or patients with comorbidities.1,2 Severely 71 
affected patients may have acute respiratory distress (15.6%) which requires invasive 72 
mechanical ventilation (14.5%) and extracorporeal membrane oxygenation (2.9%).4 73 
Possible cardiac effects of SARS-COV-2 corona virus 74 
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 A registry of 1099 cases with COVID-19 reported a higher prevalence of hypertension 75 
(23.7% vs. 13.4%) and coronary artery disease (5.8% vs. 1.8%) in severely affected versus 76 
non-severely affected patients.4 Another study, of 138 hospitalized COVID-19 77 
patients compared patients admitted to the intensive care unit (ICU) and non-ICU patients. 78 
Higher rates of hypertension (58.3% vs. 21.6%, p <0.001) and cardiovascular disease (25.0% 79 
vs. 10.8%, p=0.04) were observed in ICU patients.1 This indicates that patients with pre-80 
existing cardiovascular disease may have a worse prognosis than others although age could be 81 
one of the confounders. Furthermore, it is also essential to understand that although most 82 
clinical presentations relate to the respiratory system, the disease may also impact on the 83 
cardiovascular system.5 Besides the respiratory system, ACE2 is expressed in the human 84 
cardiovascular system including the heart6 and a number of mechanisms have been put forward 85 
whereby SARS-CoV-2 may cause myocardial injury. These include mechanisms involving 86 
derangement of ACE2 signal pathways (animal studies have shown that cellular ACE2 levels 87 
decrease upon SARS-CoV infection),6 cytokine storm and myocarditis.7,8 Occurrence of 88 
myocardial involvement and severity thereof varies among affected individuals. While 89 
myocardial damage evidenced by high cardiac markers such as hs-TnI has been 90 
recognized9 and fulminant myocarditis has been reported,8 whether cardiovascular 91 
complications include malignant arrhythmias is not yet known. In the afore-mentioned study 92 
of 138 hospitalized COVID-19 patients, arrhythmia (not further specified) was reported in 17% 93 
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of total patients and in 16 of 36 patients admitted to the ICU.1 Therefore, an arrhythmogenic 94 
effect of COVID-19 could be expected, potentially contributing to disease outcome. This may 95 
be of importance for patients with an increased risk for cardiac arrhythmias, either secondary 96 
to acquired conditions, co-morbidities, or consequent to inherited syndromes. Management of 97 
patients with inherited arrhythmia syndromes such as Long QT syndrome, Brugada syndrome, 98 
Short QT syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia in the 99 
setting of the COVID-19 pandemic may prove particularly challenging. Depending on the 100 
inherited defect involved, these patients may be susceptible to pro-arrhythmic effects of 101 
COVID-19-related issues such as fever, stress, electrolyte disturbances and use of antiviral 102 
drugs. Hence, additional precautions and preventive measures are recommended, including 103 
ECG monitoring, aggressive antipyretic treatment, and more stringent social distancing to 104 
prevent infection.10 We here describe the potential COVID-19 associated risks and therapeutic 105 
considerations for patients with distinct inherited arrhythmia syndromes and provide 106 
recommendations for their monitoring and management during this pandemic. 107 
Long QT syndrome 108 
The Long QT syndrome (LQTS) is characterised by abnormally prolonged ventricular 109 
repolarization and an increased risk of the malignant arrhythmia Torsades de Pointes and 110 
ventricular fibrillation that may lead to sudden death. LQTS is an inheritable condition caused 111 
by pathogenic variants in genes encoding ion channels (primarily KCNQ1, KCNH2, SCN5A). 112 
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An often-faced clinical situation, however, is acquired QT-interval prolongation, that occurs 113 
for instance during myocardial ischemia, hypothermia, as a result of treatment with a wide 114 
range of drugs, hypokalaemia or sepsis. Severe QTc-prolongation due to these conditions might 115 
similarly result in malignant arrhythmias. Rather commonly, patients who have severe forms 116 
of acquired QT-prolongation also have a genetic predisposition for QTc-prolongation,11,12 but 117 
without such extreme provocation these patients generally have normal QT-intervals. In fact, 118 
many LQTS patients may also have QT-intervals within normal limits in resting conditions,13 119 
although this still puts them at higher risk for malignant arrhythmias,14 especially during 120 
provocations such as the use of QTc-prolonging drugs.15 Whereas severe forms of inherited 121 
LQTS often surface during (early) childhood (from infants to adolescents),14,16 acquired QT-122 
prolongation generally occurs in older patients because these critical provocative events more 123 
often occur in older patients. 124 
Long QT syndrome and COVID-19 125 
There are several issues that require attention when discussing COVID-19 in relation to 126 
inheritable or acquired QT-prolongation.  127 
The most important determinant of risk for malignant arrhythmias in patients with LQTS 128 
or in acquired QT-prolongation, is the use of one or more QTc prolonging drugs in the setting 129 
of severe manifestations of COVID-19. Many drugs (either with cardiac or non-cardiac 130 
indications) have the ability to block cardiac potassium currents, impairing ventricular 131 
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repolarisation with subsequent prolongation of the QT-interval and an increased risk for 132 
malignant arrhythmias.15 In addition, many drugs may alter drug metabolism, e.g. due to 133 
inhibition of CYP3A4, which may further increase plasma levels of QT-prolonging drugs and 134 
further increase risk. Of special interest in COVID-19 is that there are indications that 135 
chloroquine and hydroxychloroquine might be of value.17  136 
Chloroquine is one of the most widely used anti-malarial drugs world-wide, but it has also 137 
been investigated as a potential broad-spectrum anti-viral drug.18 Amongst its mechanisms, 138 
chloroquine appears to interfere with the terminal glycosylation of ACE2 and may thus 139 
negatively influence virus-receptor binding and abrogate infection.19-21 However, chloroquine 140 
is closely related to quinidine, and while the latter is used as an anti-arrhythmic drug in Brugada 141 
syndrome and idiopathic forms of ventricular fibrillation, it is also well known for its QT-142 
prolonging effects and has been associated with QT related malignant arrhythmias. Luckily, 143 
the QT-prolonging effect of chloroquine is very modest, and in general it does not result in 144 
clinically significant QT-prolongation in patients without LQTS.22 Hydroxychloroquine sulfate, 145 
a less toxic derivative of chloroquine, is widely used in the chronic treatment of autoimmune 146 
diseases without significant effects on ECG parameters,23 and was recently shown to also 147 
efficiently inhibit SARS-CoV-2 infection in vitro.24 However, both chloroquine and 148 
hydroxychloroquine are metabolised by CYP3A4, and COVID-19 treatment with 149 
(hydroxy)chloroquine can be combined with additional anti-viral treatments such as ritonavir 150 
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plus lopinavir (both potent CYP3A4 inhibiting drugs; their combination is associated with QT-151 
prolongation), azithromycin (besides a macrolide antibiotic also investigated for its antiviral 152 
properties, with also (weak) CYP3A4 inhibition and associated with QT-prolongation)25,26, or 153 
remdesivir (an investigational drug for which metabolism and possible QT prolonging effects 154 
are not yet resolved). Combining (hydroxy)chloroquine with these drugs might thus result in 155 
higher plasma levels and significant QT-prolongation. Hence, we advise monitoring QT-156 
intervals and cardiac rhythm if starting these drugs given the increased risk for malignant 157 
arrhythmias (Figure 1). In addition, physicians should be aware of the alpha-blocking effects 158 
of (hydroxy)chloroquine, which might result in hypotension. 159 
Another issue is fever. The effect of fever is, in contrast to patients with for example BrS 160 
(see below), much less evident in patients with LQTS. A possible exception are patients, with 161 
specific LQTS 2 mutations, presenting with fever-triggered arrhythmias which are based on 162 
temperature sensitive mutant channels (i.e. less current with higher temperature).27 As most 163 
patients hospitalised for COVID-19 have fever,4 patients with known LQTS will thus generally 164 
not be at increased risk. The separate contribution of fever in acquired QT-prolongation is not 165 
well known, but sepsis is a denominator of risk of acquired QT-prolongation28, and septic shock 166 
is one of the clinical scenarios in COVID-19.4  167 
Finally, interpretation of the QT-interval is not easy,29 but guidance is available.13 While 168 
COVID-19 patients admitted to Intensive Care Units will often have continuous ECG 169 
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monitoring available, ECG monitoring of inpatients who are being treated in an airborne 170 
isolation room can be challenging. Nevertheless, if possible, we advise (Figure 1) to 171 
monitor QT-intervals at baseline and at 4h after administration of (hydroxy)chloroquine and/or 172 
anti-viral therapy in patients with congenital or acquired LQTS, patients already taking other 173 
QT-prolonging drugs, and patients with structural heart disease or bradycardia. A second ECG 174 
is recommended after 1-3 days. In all other patients, QTc-interval monitoring should be 175 
performed 24h after start of therapy. During the course of (hydroxy)chloroquine and/or anti-176 
viral therapy, QTc-interval monitoring is furthermore indicated in case of worsening 177 
kidney/liver function and electrolyte disorders (in particular K+, Ca2+ and Mg2+), especially in 178 
LQTS patients or patients with abnormal QT-intervals at baseline. Of particular concern is the 179 
COVID-19 associated diarrhea which may lead to hypokalemia with adverse effects on the 180 
QTc interval. In addition, beta-blocker treatment should be considered if the patient is not yet 181 
treated. Cardiologists throughout Europe, Canada and the US have initiated a QT-interval 182 
registry for COVID-19 patients treated with chloroquine, hydroxychloroquine and/or anti-viral 183 
drugs and contribution is open to all. 184 
In summary, we advise (Figure 1): 185 
• QTc-interval monitoring when using (hydroxy)chloroquine in COVID-19 patients 186 
• QTc-interval monitoring when using or combining anti-viral drugs in COVID-19 187 
patients  188 
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• QTc-interval monitoring in patients with known LQTS, acquired QT-prolongation or 189 
conditions associated with acquired QT-prolongation (e.g. use of other QT-prolonging 190 
drugs, structural heart disease, bradycardia <50/min, liver and renal disease) 191 
• When QTc is above 500msec, we advise consultation with a cardiologist (“QT-192 
specialist”) for guidance (which might, e.g., result in intensified monitoring, raising 193 
potassium levels, and/or discontinuation of one or more QT-prolonging drugs) 194 
• Patients with acquired LQTS or patients using a combination of QT-prolonging drugs 195 
should have a high serum potassium level. Avoiding hypokalemia is not enough and 196 
the adagium should be "a serum potassium of 5 is better than 4."30 197 
Brugada syndrome 198 
Brugada syndrome (BrS) is a familial arrhythmia syndrome disorder characterized by the 199 
type 1 Brugada ECG pattern in the right precordial leads of the ECG (coved type ST-elevation 200 
and T wave inversion in lead V1 and/or V2) and an increased risk for ventricular fibrillation 201 
and sudden cardiac death. Up to 30% of patients with BrS carry a loss-of-function pathogenic 202 
variant (mutation) in SCN5A, the gene that encodes the cardiac sodium channel, as the 203 
pathophysiological substrate of their disease.31 The most frequently used drugs for SARS-CoV-204 
2 and COVID-19 patients are not on the list of drugs to be avoided by BrS patients.32 However, 205 
attention to BrS patient management is relevant in the setting of the SARS-CoV-2 outbreak 206 
since ECG manifestations of the disorder may be uncovered during fever, and since fever has 207 
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been unequivocally associated with life-threatening arrhythmic events (LTE) in patients with 208 
the disorder.33 209 
The importance of fever in BrS patients is now well-established.33-35 In 24 patients with 210 
BrS, 3 of whom had a fever-triggered cardiac arrest, the increase in body temperature reduced 211 
the PR interval in control individuals, but increased PR interval, QRS width, and the maximum 212 
J-point in BrS patients.34 Another study showed that fever-associated BrS seems to be 213 
associated with a higher future risk of LTE’s compared to drug-induced type 1 pattern.35 Finally, 214 
fever seems to be particularly relevant in children.33 Indeed, in a registry with symptomatic 215 
BrS patients (the SABRUS registry) approximately 6% of LTE’s were associated with fever 216 
and the highest rate of fever-triggered LTE’s was observed in the very young (65%, age ≤5 217 
years). In the age range 16 to 70 years, only 4% of the LTE’s was related to fever. In the elderly 218 
(>70 years) this percentage increased to 25%.33 219 
In the setting of fever, the presence of a pathogenic variant in SCN5A may be particularly 220 
relevant. In a single center series of 111 patients with BrS, 22 presented with a cardiac arrest, 221 
4 of which were fever related. Three of these 4 patients harbored a pathogenic variant in 222 
SCN5A.34 In the SABRUS registry, the percentage of SCN5A pathogenic variants was 77% in 223 
children and 27% in adults with a LTE.33 The authors also performed an analysis of all 224 
published cases (up to 2018) with fever-triggered LTE’s (40 patients in 22 reports) revealed 225 
the presence of a putatively pathogenic variant in SCN5A was found in 13 (68%) of 19 patients 226 
13 
©2020 Heart Rhythm accepted for publication. Heart Rhythm 2020;xx:xx-xx. 
tested.33 Moreover, in a multicenter pediatric population of 106 patients, 10 patients had a LTE 227 
during follow-up, which was triggered by fever in 27%; all of the latter patients were positive 228 
for a pathogenic SCN5A variant. Finally, preliminary data in a pediatric cohort indicated that 229 
mainly children with a SCN5A mutation developed a type 1 ECG during fever (43.8% of 230 
children who developed a type 1 ECG during fever had a SCN5A mutation vs 4.2% of children 231 
without a type 1 during fever) and had events during follow-up (7/21 vs 0/47).36 These studies 232 
collectively indicate that sodium channel function is sensitive to temperature. This sensitivity 233 
may be due to altered temperature-sensitive kinetics, in particular accelerated inactivation,37 234 
and/or decreased sodium channel expression at higher temperatures.38 Also in other sodium 235 
channel mediated diseases, increased temperature sensitizes patients to disease-related 236 
symptoms.39,40 237 
Based on the above we feel that the following recommendations are pertinent:  238 
1. All patients with Brugada syndrome should self-treat with 239 
paracetamol/acetaminophen immediately if they develop signs of fever and self-isolate. 240 
2. Patients without an ICD who are at higher risk due to fever include: 241 
a. sodium channel disease with or without a type 1 ECG pattern, 242 
b. children and young adults (under 26 years old) and the elderly (over 70 years) 243 
with Brugada syndrome; and 244 
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c. all patients with a spontaneous type 1 Brugada pattern and/or cardiac syncope.   245 
3. If these higher risk patients develop a high fever (>38.5C) despite paracetamol 246 
treatment, they will need to attend the emergency department*. The emergency 247 
department must be forewarned to allow assessment by staff with suitable protective 248 
equipment. Assessment should include an ECG** and monitoring for arrhythmia. If an 249 
ECG shows the type 1 Brugada ECG pattern, then the patient will need to be observed 250 
until fever and/or the ECG pattern resolves. If all ECGs show no sign of the type 1 ECG 251 
pattern, then they can go home to self-isolate. 252 
4. Patients who are not part of the higher risk group and have a drug-induced type 1 ECG 253 
pattern, no symptoms of syncope and no sign of a spontaneous type 1 pattern at any 254 
other time are at lowest risk and can afford to self-isolate at home. The risk of visiting 255 
the emergency department and contracting COVID-19 is likely to outweigh the risk of 256 
a LTE. Attendance at hospital should then be dictated by other clinical features, such 257 
as palpitations or (pre-)syncope etc. The same advice holds for patients with an ICD. 258 
* attendance at the emergency department may require regulation according to the capacity 259 
of service and risk of COVID-19 infection. 260 
** ideally three different ECGs with V1 and V2 in the 4th, 3rd and 2nd intercostal spaces 261 
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Management in the hospital should include monitoring of ECG abnormalities and 262 
arrhythmia, as well as efforts to reduce the body temperature (with antipyretic drugs, preferably 263 
paracetamol/acetaminophen, or eventually ibuprofen). More generally, BrS patients, in 264 
particular those with a pathogenic or likely pathogenic variant in SCN5A, are advised to self-265 
isolate in their private environment. 266 
Short QT syndrome 267 
Short QT syndrome (SQTS) is a familial arrhythmia syndrome characterized by short QT 268 
intervals on the ECG and a significant rate of ventricular arrhythmias.41 It is a heterogeneous 269 
disease caused by pathogenic variants in at least three different potassium channel genes 270 
(KCNH2, KCNQ1 and KCNJ2) and the cardiac chloride-bicarbonate exchanger gene 271 
(SLC4A3).42 It is an extremely rare disease; in a recent systematic literature review only 110 272 
cases were described.43 No specific triggers for LTE, including fever, have been described. 273 
Hence, based on current knowledge, SQTS patients do not seem to be at particular risk when 274 
they are affected by COVID-19. 275 
Potential drugs for COVID-19 patients, like chloroquine, might actually be beneficial for 276 
SQTS patients due to lengthening of their QT-interval, as has been suggested by modelling 277 
data for SQTS type 1 (KCNH2-related44) and type 3 (KCNJ2 related44,45). There are no clinical 278 
data as far as we are aware. 279 
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We therefore do not believe that there is a particular concern when SQTS patients are 280 
infected with SARS-CoV-2. 281 
Catecholaminergic Polymorphic Ventricular Tachycardia 282 
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a familial arrhythmia 283 
syndrome characterized by adrenergic-related ventricular arrhythmias (i.e. during exercise, or 284 
stress).41 It is a heterogeneous disease with pathogenic variants in RYR2 encoding the human 285 
Ryanodine receptor 2 as the most important contributor.46 First line treatment comprises 286 
intensive beta blocker therapy. In insufficiently responsive cases flecainide should be added or 287 
left sympathetic denervation should be conducted.41,46 ICD therapy should be avoided.47  288 
As mentioned above, exercise and emotional circumstances constitute specific triggers for 289 
LTE. An increased heart rate alone (pacing-induced), as an important symptom of fever, does 290 
not appear to be sufficient for the induction of ventricular arrhythmias.48 Fever, as a specific 291 
trigger has not been described. Whether or not the stressful circumstances that COVID-19 292 
patients find themselves in will lead to an increased burden of arrhythmias can only be 293 
speculated upon. 294 
The antiviral therapy proposed for COVID-19 is not expected to lead to increased risk. 295 
The only potential deleterious pharmacological interaction in these patients are drugs with 296 
alpha or beta adrenoceptor mimetic activity, which may be used in cases in need of 297 
hemodynamic support. Intravenous epinephrine has been used to unmask ventricular 298 
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arrhythmias and initial data suggested that epinephrine was more effective than exercise testing 299 
in unmasking ventricular arrhythmias.49 Later studies revealed, however, a low sensitivity and 300 
high specificity (with the exercise test as the gold standard50). Nevertheless, based on their 301 
pathophysiological mechanism of action, epinephrine, isoproterenol and dobutamine, all alpha 302 
and/or B1 receptor agonists, should probably be avoided. Milrinone, the most widely used 303 
phosphodiesterase 3 inhibitor, acts by decreasing the degradation of cyclic adenosine 304 
monophosphate (cAMP). This may potentially stimulate the RyR2 receptor and must thus be 305 
used with caution. However, with continuation of the beta blockers (as we recommend, see 306 
below) this may not be that relevant because betablockers suppress milrinone-induced 307 
increased Ca-leak.51 CPVT patients, in particular those who were symptomatic prior to 308 
diagnosis, should stay on their beta blocker treatment with or without flecainide as long as is 309 
tolerated hemodynamically. Flecainide does have interactions with Ritonavir/Lopinavir and 310 
chloroquine, yet we believe that it is an important enough therapy not to stop in these 311 
particularly stressful circumstances. 312 
Based on the above we also suggest avoidance of epinephrine in the setting of a VT/VF 313 
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Patients with inherited arrhythmia syndromes may be at an increased pro-arrhythmic risk 317 
in the setting of COVID-19 infection, necessitating additional precautions and specialized 318 
management. Preventive measures should include stringent social distancing to prevent 319 
infection, aggressive antipyretic treatment to reduce fever in Brugada syndrome patients, and 320 
ECG monitoring in Long QT syndrome patients treated with antiviral drugs. 321 
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Figure legends 454 
Figure 1: Flowchart of proposed guidance of QTc monitoring in patients receiving 455 
(hydroxy-)chloroquine and/or antiviral drugs and /or azathromycin. It should be noted that not 456 
every LQTS patient has the same risk. The length of the QTc interval is of importance (as is 457 
implicit in the flowchart) but also gender, age and the genotype are important. LQT2 patients 458 
may be at higher risk than LQT1 patients for example. The consulted cardiologist should have 459 
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